KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Progyny (PGNY) EBITDA (2018 - 2025)

Historic EBITDA for Progyny (PGNY) over the last 8 years, with Q3 2025 value amounting to $21.5 million.

  • Progyny's EBITDA rose 7279.66% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.8 million, marking a year-over-year increase of 3112.05%. This contributed to the annual value of $67.5 million for FY2024, which is 847.65% up from last year.
  • As of Q3 2025, Progyny's EBITDA stood at $21.5 million, which was up 7279.66% from $24.4 million recorded in Q2 2025.
  • In the past 5 years, Progyny's EBITDA registered a high of $24.4 million during Q2 2025, and its lowest value of -$188000.0 during Q4 2021.
  • Over the past 5 years, Progyny's median EBITDA value was $13.8 million (recorded in 2023), while the average stood at $13.4 million.
  • In the last 5 years, Progyny's EBITDA crashed by 11619.29% in 2021 and then soared by 2598103.45% in 2023.
  • Progyny's EBITDA (Quarter) stood at -$188000.0 in 2021, then skyrocketed by 1858.51% to $3.3 million in 2022, then soared by 317.42% to $13.8 million in 2023, then grew by 14.4% to $15.8 million in 2024, then soared by 36.36% to $21.5 million in 2025.
  • Its EBITDA was $21.5 million in Q3 2025, compared to $24.4 million in Q2 2025 and $24.2 million in Q1 2025.